Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

(2017) György Németh et al.   LANCET

An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression

(2016) Suresh Durgam et al.   AMERICAN JOURNAL OF PSYCHIATRY

Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology

(2016) Jo C. Neill et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

The dopamine D 3 -preferring D 2 /D 3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia

(2016) David J.G. Watson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants

(2016) Suresh Durgam et al.   JOURNAL OF CLINICAL PSYCHIATRY

Altering the course of schizophrenia: progress and perspectives

(2016) Mark J. Millan et al.   NATURE REVIEWS DRUG DISCOVERY

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO

(2016) Ragy R. Girgis et al.   PSYCHOPHARMACOLOGY

Cariprazine in Acute Exacerbation of Schizophrenia

(2015) Suresh Durgam et al.   JOURNAL OF CLINICAL PSYCHIATRY

Glutamate and dopamine in schizophrenia: An update for the 21st century

(2015) Oliver Howes et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Occupancy of Dopamine D3 Receptors by Aripiprazole in Treatment Resistant Late-Life Depressed Patients Depends on Length of Treatment as Evidenced by in vivo Imaging with [11C]-(+)-PHNO

(2014) Fernando Caravaggio et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial

(2014) Suresh Durgam et al.   SCHIZOPHRENIA RESEARCH

Correlation between the effects of local and intracerebroventricular infusions of galanin on 5-HT release studied by microdialysis, and distribution of galanin and galanin receptors in prefrontal cortex, ventral hippocampus, amygdala, hypothalamus, and st

(2014) Shimako Yoshitake et al.   SYNAPSE

Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: A translational link to humans

(2013) Joanna C. Neill et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Altered Cortical GABA Neurotransmission in Schizophrenia: Insights into Novel Therapeutic Strategies

(2012) Ana D. Stan et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse

(2012) Ross Zimnisky et al.   PSYCHOPHARMACOLOGY

Poster #16 CARIPRAZINE, A D3/D2 DOPAMINE RECEPTOR PARTIAL AGONIST ANTIPSYCHOTIC, DISPLAYS GREATER D3 RECEPTOR OCCUPANCY IN VIVO COMPARED WITH OTHER ANTIPSYCHOTICS

(2012) Bela Kiss et al.   SCHIZOPHRENIA RESEARCH

Serotonin 2A receptor antagonists for treatment of schizophrenia

(2011) Bjørn H Ebdrup et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Increased prefrontal cortical D1 receptors in drug naïve patients with schizophrenia: a PET study with [11C]NNC112

(2011) Anissa Abi-Dargham et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents

(2011) István Gyertyán et al.   NEUROCHEMISTRY INTERNATIONAL

Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats

(2011) Nurith Amitai et al.   NEUROPHARMACOLOGY

Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO

(2011) Romina Mizrahi et al.   SCHIZOPHRENIA RESEARCH

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

(2010) JC McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile

(2010) B. Kiss et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex

(2010) Mirjana Carli et al.   PSYCHOPHARMACOLOGY

The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors

(2009) Ariel Graff-Guerrero et al.   ARCHIVES OF GENERAL PSYCHIATRY

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15

(2008) István Gyertyán et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15

(2008) Béla Kiss et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY